Zymeworks Secures Second FDA Nod for Ziihera in HER2+ Gastroesophageal Cancer
Event summary
- FDA approves Ziihera (zanidatamab-hrii) with or without tislelizumab plus chemotherapy for first-line HER2+ gastroesophageal adenocarcinoma on August 25, 2026.
- Approval triggers a $250 million milestone payment from Jazz Pharmaceuticals, with potential for up to $1.3 billion in additional milestones and 20% royalties.
- Zymeworks eligible for up to $144 million in additional milestones and 19.5% royalties from BeOne Medicines in Asia Pacific.
- Approval supported by Phase 3 HERIZON-GEA-01 trial results published in the New England Journal of Medicine.
The big picture
This approval validates Zymeworks' Azymetric™ bispecific antibody platform and reinforces its strategy of partnering with global biopharmaceutical companies to expand the reach of its therapeutics. The milestone payments and royalty streams strengthen Zymeworks' cash flow strategy, supporting its internal R&D pipeline and potential return of capital to shareholders. The success of zanidatamab in multiple tumor types underscores the potential of bispecific antibodies in oncology.
What we're watching
- Royalty Revenue
- How the approval will impact Zymeworks' long-term royalty streams from Jazz and BeOne.
- Pipeline Expansion
- Whether Zymeworks can leverage this success to advance its wholly-owned pipeline of trispecific T-cell engagers and antibody-drug conjugates.
- Regulatory Momentum
- The pace at which Jazz pursues additional regulatory approvals for zanidatamab in other global markets.
Related topics